Allergic Asthma Clinical Trial
Official title:
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
Chronic airway inflammation rich in eosinophils is an important feature seen in asthma.
Airway and blood eosinophilia is associated with increased rates of asthma exacerbations and
more intense treatment.
Recently, the existence of two distinct eosinophils subtypes was revealed-lung-resident
eosinophils (rEOS), which maturate independently to interleukin (IL) 5, with the primary
function to maintain tissue homeostasis, and inflammatory eosinophils (iEOS), which mature in
IL-5-dependent manner and are mainly involved in immune responses. Eosinophils' effect on the
airway remodeling in asthma depends not only on the activity but also by their viable number
in the lungs. Blood iEOS infiltrate the airways mainly after the environmental stimulus like
allergen and leave the airways with bronchial secretions. However, rEOS reside lung tissue
for their entire lifetime regulating local immunity. Blood rEOS and iEOS ratio alters in
asthma, compared with healthy controls. It is known that the predominant eosinophils subtype
in allergic asthma are iEOS, while rEOS are basic subtype in severe eosinophilic asthma
patients, moreover, they are different in adhesive properties and survivability as well.
Distinct biological properties allows to speculate about their different functions in asthma,
however, there are still little information. Data about differently expressed microRNA
(miRNA) profiles in eosinophils in asthma suggests, that eosinophils subtypes can be distinct
in non-coding RNA (ncRNA) - microRNA (miRNA), piwi-interacting RNA (piRNA) and long
non-coding RNA (IncRNA) profiles that could describe their role in asthma pathogenesis and
act as biomarkers to discern asthma phenotypes.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | October 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Men and women between the ages of 18-70 years; - Allergic asthma and sensitization to house dust mites (D. pteronyssinus) allergen, approved with: 1) medical history and symptoms more than one year; 2) skin prick test positive for D. pteronyssinus (positive wheals are those exceeding 3 mm in diameter greater than the negative control); 3) positive bronchial challenge with methacholine or documented reversible bronchial obstruction; - Severe eosinophilic asthma; - Premenopausal women if pregnancy test is negative; - Healthy subjects without allergic and other chronic respiratory diseases (control group); - Participants who gave his/her informed written consent. Exclusion Criteria: - Asthma exacerbation 1 month prior to study; - Clinically significant permanent allergy symptoms (ex. cat or dog dander induced allergy); - Contraindications to perform an allergy skin test and/or bronchial provocation test: 1) active airway infection 1 month prior the study; 2) used medicaments: inhaled glucocorticoids intake 1 month prior the study, antihistamines intake 7 days prior the study; 3) short acting ß2 agonists 12 hours prior the study; 4) long acting ß2 agonists 2 days prior the study; 5) leukotriene receptor antagonists prior 14 days; - Contraindications for epinephrine; - Other significant mental and / or internal diseases and conditions, which could be as exclusion criteria due to the opinion of the researcher; - Alcohol or narcotic abuse; - Pregnancy; - Breast-feeding. |
Country | Name | City | State |
---|---|---|---|
Lithuania | Lithuanian University of Health Sciences, Pulmonology Department | Kaunas |
Lead Sponsor | Collaborator |
---|---|
Lithuanian University of Health Sciences |
Lithuania,
Barnig C, Alsaleh G, Jung N, Dembélé D, Paul N, Poirot A, Uring-Lambert B, Georgel P, de Blay F, Bahram S. Circulating Human Eosinophils Share a Similar Transcriptional Profile in Asthma and Other Hypereosinophilic Disorders. PLoS One. 2015 Nov 2;10(11):e0141740. doi: 10.1371/journal.pone.0141740. eCollection 2015. — View Citation
Mazzeo C, Cañas JA, Zafra MP, Rojas Marco A, Fernández-Nieto M, Sanz V, Mittelbrunn M, Izquierdo M, Baixaulli F, Sastre J, Del Pozo V. Exosome secretion by eosinophils: A possible role in asthma pathogenesis. J Allergy Clin Immunol. 2015 Jun;135(6):1603-13. doi: 10.1016/j.jaci.2014.11.026. Epub 2015 Jan 21. — View Citation
Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Janss T, Starkl P, Ramery E, Henket M, Schleich FN, Radermecker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet C, Marichal T, Bureau F. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016 Sep 1;126(9):3279-95. doi: 10.1172/JCI85664. Epub 2016 Aug 22. — View Citation
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28. — View Citation
Perry MM, Tsitsiou E, Austin PJ, Lindsay MA, Gibeon DS, Adcock IM, Chung KF. Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respir Res. 2014 May 16;15:58. doi: 10.1186/1465-9921-15-58. — View Citation
Rodrigo-Muñoz JM, Cañas JA, Sastre B, Rego N, Greif G, Rial M, Mínguez P, Mahíllo-Fernández I, Fernández-Nieto M, Mora I, Barranco P, Quirce S, Sastre J, Del Pozo V. Asthma diagnosis using integrated analysis of eosinophil microRNAs. Allergy. 2019 Mar;74(3):507-517. doi: 10.1111/all.13570. Epub 2018 Oct 11. — View Citation
Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013 Jan;13(1):9-22. doi: 10.1038/nri3341. Epub 2012 Nov 16. Review. — View Citation
Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147-74. Review. — View Citation
Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017 Dec;17(12):746-760. doi: 10.1038/nri.2017.95. Epub 2017 Sep 11. Review. — View Citation
Zhu Y, Mao D, Gao W, Han G, Hu H. Analysis of lncRNA Expression in Patients With Eosinophilic and Neutrophilic Asthma Focusing on LNC_000127. Front Genet. 2019 Mar 19;10:141. doi: 10.3389/fgene.2019.00141. eCollection 2019. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fold changes of ncRNA expression between eosinophils subtypes | Validated ncRNA expression of rEOS and iEOS in severe and non-severe eosinophilic asthma patients and healthy subjects. | From 6 to 12 months | |
Primary | ncRNA levels in rEOS- and iEOS-derived exosomes | Qualitative and quantitative selected ncRNA levels in rEOS- and iEOS-derived exosomes of all investigated groups. | From 12 to 18 months | |
Secondary | Fold changes of ncRNA profiles of distinct eosinophil subtypes | Non-validated whole ncRNA profiles of distinct eosinophil subtypes in severe and non-severe eosinophilic asthma patients and healthy subjects. | From 6 to 12 months | |
Secondary | The fold changes of rEOS and iEOS surface integrins expression | The gene expression of selected outer-membrane integrins in eosinophil subtypes. | From 6 to 12 months | |
Secondary | The fold changes of rEOS and iEOS eosinophilopoietins receptors expression | The gene expression of interleukin (IL)-5, IL-3, and granulocyte-macrophage colony-stimulating factor in eosinophil subtypes. | From 6 to 12 months | |
Secondary | The efficiency of iEOS and rEOS adhesion | The differences in stable adhered iEOS and rEOS quantity in the combined cell culture with airway smooth muscle (ASM) cells or pulmonary fibroblasts compared between the investigated groups. | From 6 to 12 months | |
Secondary | iEOS and rEOS survival differences | Viable iEOS and rEOS number after an appropriate period of time in combined cell culture with ASM cells or pulmonary fibroblasts. | From 6 to 12 months | |
Secondary | Quantity of iEOS and rEOS synthesized reactive oxygen species | Relative differences between iEOS and rEOS synthesized reactive oxygen species quantity after an appropriate period of incubation alone or with ASM cells or pulmonary fibroblasts. | From 6 to 12 months | |
Secondary | Apoptotic iEOS and rEOS number | The number of apoptotic iEOS and rEOS after an appropriate period of time in combined cell culture with ASM cells or pulmonary fibroblasts. | From 6 to 12 months | |
Secondary | Concentrations of iEOS and rEOS produced proteins in investigated subjects' body fluids. | Selected iEOS and rEOS proteins concentrations, measured in investigated subjects body fluids, expressed as the amount of protein in the respective amount of fluid sample. | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on airway smooth muscle cells or pulmonary fibroblasts proliferation | The quantity of ASM cells or pulmonary fibroblasts after several repeats of proliferation in the presence or absence of eosinophil subtypes. | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on apoptotic ASM cells and pulmonary fibroblasts number | The number of apoptotic ASM cells and pulmonary fibroblasts after an appropriate period of time in combined cell culture with iEOS and rEOS. | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on migration of ASM cells. | The migrated ASM cells number after an appropriate period of time in combined cell culture with iEOS and rEOS | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on migration of pulmonary fibroblasts | The migrated pulmonary fibroblasts number after an appropriate period of time in combined cell culture with iEOS and rEOS | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on ASM cells contractility | The relative efficiency of ASM cells' ability to contract collagen gel after an appropriate period of time in combined cell culture with iEOS and rEOS, expressed as reduced poured gel size in percentage, compared with control ASM cells without incubation with eosinophils. | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on pulmonary fibroblasts contractility | The relative efficiency of pulmonary fibroblasts ability to contract collagen gel after an appropriate period of time in combined cell culture with iEOS and rEOS. expressed as reduced poured gel size in percentage, compared with control pulmonary fibroblasts, without incubation with eosinophils. | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins expression; | Altered selected ASM cells and pulmonary fibroblasts proteins expression, after incubation with iEOS and rEOS, expressed as fold changes in comparison with control cells, without incubation with eosinophils | From 6 to 12 months | |
Secondary | iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins gene expression; | Altered selected ASM cells and pulmonary fibroblasts proteins gene expression, after incubation with iEOS and rEOS, expressed as fold changes in comparison with control cells, without incubation with eosinophils | From 6 to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Completed |
NCT02911688 -
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
|
Phase 2 | |
Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
Completed |
NCT00999466 -
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
|
Phase 2 | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|
||
Withdrawn |
NCT04401631 -
Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation
|